Skye Bioscience Inc. (SKYE), a clinical-stage biotechnology company developing new treatments that help reduce excess body fat and improve metabolic health, has a clinical trial catalyst to watch in the near term.
The company's lead drug candidate is Nimacimab, a peripherally acting antibody targeting the cannabinoid 1 receptor ("CB1"), which has been implicated as an important target in cardiometabolic diseases, including obesity and renal complications.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.